Richard Scheller
Chief Tech/Sci/R&D Officer at BRIDGEBIO PHARMA, INC.
Net worth: 2 M $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| J. Judice | M | 61 |
DiCE Molecules, Inc.
 DiCE Molecules, Inc. Packaged SoftwareTechnology Services DiCE Molecules, Inc. is a private company that focuses on immunology and small molecule discovery. The company is based in Menlo Park, CA. The company's goal is to provide convenient oral medicines with biologic-like efficacy to patients with chronic diseases. The company was founded by J. Kevin Judice and he has been the CEO since incorporation. | - |
| Jim Scopa | M | 65 |
DICE Molecules SV, Inc.
 DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | 4 years |
| Jake Simson | M | 38 |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | 4 years |
| Shaan Gandhi | M | 38 |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | 4 years |
| Charles Homcy | M | 75 |
BridgeBio Pharma LLC
 BridgeBio Pharma LLC BiotechnologyHealth Technology BridgeBio Pharma LLC engages in the discovery and development of pharmaceutical drugs for patients with genetic diseases. It offers transthyretin stabilizer, SHP2 inhibitor, KRAS inhibitor, Collagen 7 replacement, and S1P-lyase inhibitor. The company was founded by Neil Kumar and is headquartered in Palo Alto, CA. | 6 years |
| Catherine Sohn | M | 71 |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | 3 years |
| Sekar Kathiresan | M | 52 |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | 2 years |
| Jonathan Lim | M | 52 |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | 5 years |
| Dan Spiegelman | M | 65 |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | 4 years |
| Eric Aguiar | M | 62 |
BridgeBio Pharma LLC
BridgeBio Pharma LLC BiotechnologyHealth Technology BridgeBio Pharma LLC engages in the discovery and development of pharmaceutical drugs for patients with genetic diseases. It offers transthyretin stabilizer, SHP2 inhibitor, KRAS inhibitor, Collagen 7 replacement, and S1P-lyase inhibitor. The company was founded by Neil Kumar and is headquartered in Palo Alto, CA. | 5 years |
| Nancy Andrews | M | 65 |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | 3 years |
| Andy Tran | M | - |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | 2 years |
| Emily Conley | M | 42 |
Medrio, Inc.
 Medrio, Inc. Data Processing ServicesTechnology Services Medrio, Inc. provides advanced electronic data capture and eClinical tools. It offers an integrated eClinical software platform with a fully hosted EDC system. Its new mobile suite, mSource, supports both event-based and subject-based workflows, offline data entry, and Patient Reported Outcomes (PRO). The company was founded by Michael Richard Novotny in 2005 and is headquartered in San Francisco, CA. | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Shehnaaz Suliman | M | 52 | 3 years | |
| William Burns | M | 76 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 10 years |
| Scott Robertson | M | 44 | 7 years | |
| Andrea Bell | M | - |
Stanford University
| 7 years |
| Michael L. Ehrman | M | 50 |
Stanford University
| 5 years |
| Lawrence S. Malkin | M | - |
Stanford University
| 4 years |
| Steven Schoch | M | 64 |
23andMe, Inc.
 23andMe, Inc. Medical SpecialtiesHealth Technology 23andMe, Inc. provides genetic information using DNA analysis technologies and web-based interactive tools. It enables individuals to gain deeper insights into personal ancestry, genealogy, and inherited traits. The company was founded by Linda Avey, Paul L. Cusenza and Anne E. Wojcicki in 2006 and is headquartered in Sunnyvale, CA. | 3 years |
| Larry Alder | M | - |
Stanford University
| 6 years |
| Mohammad Ali Hassan Mohammad Ikwan | M | - |
Stanford University
| 3 years |
| Harold H. Montgomery | M | 64 |
Stanford University
| 2 years |
| Erik Falk | M | 54 |
Stanford University
| 4 years |
| Randy Chappel | M | - |
Stanford University
| 7 years |
| Faisal Hamad bin Abdullah Al-Sugair | M | 64 |
Stanford University
| 5 years |
| Nasser Mustafa Mohamed Saad Khraishi | M | 62 |
Stanford University
| 5 years |
| Dean Schorno | M | 61 |
23andMe, Inc.
23andMe, Inc. Medical SpecialtiesHealth Technology 23andMe, Inc. provides genetic information using DNA analysis technologies and web-based interactive tools. It enables individuals to gain deeper insights into personal ancestry, genealogy, and inherited traits. The company was founded by Linda Avey, Paul L. Cusenza and Anne E. Wojcicki in 2006 and is headquartered in Sunnyvale, CA. | 3 years |
| Gary Zweiger | M | - |
Stanford University
| 11 years |
| George Koutentakis | M | - |
Stanford University
| 4 years |
| Derek R. Armfield | M | - |
Stanford University
| 5 years |
| Augie Fabela | M | 58 |
Stanford University
| 5 years |
| Chris Jones | M | 56 |
Stanford University
| 5 years |
| David Tony Lillios | M | - |
Stanford University
| 5 years |
| Mark V. Matthews | M | - |
Stanford University
| 6 years |
| Alan W. Marty | M | - |
Stanford University
| 2 years |
| Christopher Petti | M | - |
Stanford University
| 7 years |
| Stephen Zachary | M | 42 | 4 years | |
| YONG TAO | M | - |
Stanford University
| 7 years |
| Susan Bryenton | F | - |
Stanford University
| 5 years |
| Yinyu Ye | M | 76 |
Stanford University
| 6 years |
| Lisa Bowers | F | 51 | 1 years | |
| Yeong-Jun Kim | M | 62 |
Stanford University
| 8 years |
| Márcio Gomes Pinto Garcia | M | 64 |
Stanford University
| 3 years |
| Theodora Varvarigou | M | - |
Stanford University
| 4 years |
| Paul Johnson | M | 39 |
23andMe, Inc.
23andMe, Inc. Medical SpecialtiesHealth Technology 23andMe, Inc. provides genetic information using DNA analysis technologies and web-based interactive tools. It enables individuals to gain deeper insights into personal ancestry, genealogy, and inherited traits. The company was founded by Linda Avey, Paul L. Cusenza and Anne E. Wojcicki in 2006 and is headquartered in Sunnyvale, CA. | 2 years |
| Stephen Fisher | M | 60 |
Stanford University
| 5 years |
| June Lee | M | 58 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 7 years |
| Julia Sze | F | 57 |
Stanford University
| 5 years |
| Tsu-Jae Liu | M | 60 |
Stanford University
| 5 years |
| Mittie Doyle | M | 59 | 1 years | |
| Michelle Corral | F | - | 1 years | |
| Ashwin Bulchandani | M | - |
Stanford University
| 5 years |
| Martin A. Fischer | M | 64 |
Stanford University
| 5 years |
| Clark E. Cohen | M | - |
Stanford University
| 4 years |
| Jeffrey Bede | M | - |
Stanford University
| 4 years |
| Tobin C. Island | M | 57 |
Stanford University
| 5 years |
| H. C Ursula Keller | M | 65 |
Stanford University
| 3 years |
| William Staib | M | - |
Stanford University
| 4 years |
| Darius C. Brooks | M | - |
Stanford University
| 4 years |
| Ryan A. Harris | M | - |
Stanford University
| 6 years |
| Charles J. Jacklin | M | 69 |
Stanford University
| 10 years |
| Steven C. Voorhis | M | - |
Stanford University
| 4 years |
| Tzar Kuoi Li | M | 59 |
Stanford University
| 4 years |
| Craig Carpenter Hoagland | M | - |
Stanford University
| 6 years |
| Selena Chaisson | M | - |
Stanford University
| 5 years |
| Kenneth McBride | M | 56 |
Stanford University
| 6 years |
| T. J. Jubeir | M | - |
Stanford University
| 4 years |
| Bradley Robert Kent | M | - |
Stanford University
| 5 years |
| Steve J. Rosston | M | 64 |
Stanford University
| 3 years |
| Jason Terrance Holzer | M | 52 |
Stanford University
| 4 years |
| Sharon Tetlow | F | 64 | 3 years | |
| Steve Jurvetson | M | 57 |
Stanford University
| 5 years |
| Stelleo Tolda | M | 55 |
Stanford University
| 5 years |
| Linda Rubinstein | F | 58 | 1 years | |
| Aron B. Anderson | M | 60 |
Stanford University
| 5 years |
| Jeff T. Soukup | M | 58 |
Stanford University
| 4 years |
| Jeff Stevens | M | - |
Stanford University
| 8 years |
| Geoff S. Keith | M | - |
Stanford University
| 5 years |
| Whitney R. White | M | - |
Stanford University
| 5 years |
| Robert Neivert | M | - |
Stanford University
| 3 years |
| Shahin Sharifzadeh | M | 59 |
Stanford University
| 4 years |
| Robert Brown | M | - |
Stanford University
| 5 years |
| Biondo L. Biondi | M | - |
Stanford University
| 3 years |
| Robert E. Burwell | M | - |
Stanford University
| 7 years |
| John P. Sullivan | M | - |
Stanford University
| 7 years |
| Michelangelo Volpi | M | 57 |
Stanford University
| 5 years |
| Bernhard E. Boser | M | - |
Stanford University
| 4 years |
| Rob Romero | M | - |
Stanford University
| 5 years |
| J. B. Holston | M | - |
Stanford University
| 3 years |
| M. Robinson | M | - |
Stanford University
| 5 years |
| Samer Hamadeh | M | - |
Stanford University
| 5 years |
| Jeffrey Loomans | M | - |
Stanford University
| 4 years |
| Jim Chung | M | - |
Stanford University
| 5 years |
| Ryan McIntyre | M | - |
Stanford University
| 4 years |
| Heather Puri | F | - |
Stanford University
| 4 years |
| Douglas A. Gentile | M | - |
Stanford University
| 2 years |
| Neal P. Kaufman | M | - |
Stanford University
| 1 years |
| Brandon H. P. Lin | M | - |
Stanford University
| 3 years |
| Mary Raymond | F | 63 |
Stanford University
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
| Switzerland | 1 | 1.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Richard Scheller
- Personal Network
